The role of endotoxin in septic shock.
Endotoxic septic shock
Endotoxin
Phenotypes
Sepsis
Septic shock
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
19 10 2023
19 10 2023
Historique:
received:
17
09
2023
accepted:
16
10
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Septic shock can be caused by a variety of mechanisms including direct effects of bacterial toxins such as endotoxin. Annually, approximately 5-7 million patients worldwide develop sepsis with very high endotoxin activity in the blood and more than half die. The term endotoxic septic shock has been used for these patients but it is important to emphasize that endotoxin may be a factor in all forms of septic shock including non-bacterial etiologies like COVID-19 since translocation of bacterial products is a common feature of septic shock. A pattern of organ failure including hepatic dysfunction, acute kidney injury and various forms of endothelial dysfunction ranging from disseminated intravascular coagulation to thrombotic microangiopathy characterize endotoxic septic shock. However, while characteristic, the clinical phenotype is not unique to patients with high endotoxin, and the diagnosis relies on the measurement of endotoxin activity in addition to clinical assessment. Therapies for endotoxic septic shock are limited with immune modulating therapies under investigation and extracorporeal blood purification still controversial in many parts of the world.
Identifiants
pubmed: 37858258
doi: 10.1186/s13054-023-04690-5
pii: 10.1186/s13054-023-04690-5
pmc: PMC10585761
doi:
Substances chimiques
Endotoxins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
400Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–11.
doi: 10.1016/S0140-6736(19)32989-7
pubmed: 31954465
pmcid: 6970225
Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23(1):196.
doi: 10.1186/s13054-019-2478-6
pubmed: 31151462
pmcid: 6545004
Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003–17.
doi: 10.1001/jama.2019.5791
pubmed: 31104070
pmcid: 6537818
Leligdowicz A, Matthay MA. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit Care. 2019;23(1):80.
doi: 10.1186/s13054-019-2372-2
pubmed: 30850013
pmcid: 6408778
Kellum JA, Formeck CL, Kernan KF, Gomez H, Carcillo JA. Subtypes and Mimics of Sepsis. Crit Care Clin. 2022;38(2):195–211.
doi: 10.1016/j.ccc.2021.11.013
pubmed: 35369943
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51.
doi: 10.1056/NEJMra1208623
pubmed: 23984731
Brinkworth JF, Valizadegan N. Sepsis and the evolution of human increased sensitivity to lipopolysaccharide. Evol Anthropol. 2021;30(2):141–57.
doi: 10.1002/evan.21887
pubmed: 33689211
Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455–63.
doi: 10.1001/jama.2018.14618
pubmed: 30304428
pmcid: 6233793
Sirivongrangson P, Kulvichit W, Payungporn S, Pisitkun T, Chindamporn A, Peerapornratana S, Pisitkun P, Chitcharoen S, Sawaswong V, Worasilchai N, et al. Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med Exp. 2020;8(1):72.
doi: 10.1186/s40635-020-00362-8
pubmed: 33284413
pmcid: 7719737
Adamik B, Smiechowicz J, Jakubczyk D, Kubler A. Elevated serum PCT in septic shock with endotoxemia is associated with a higher mortality rate. Medicine. 2015;94(27): e1085.
doi: 10.1097/MD.0000000000001085
pubmed: 26166090
pmcid: 4504546
van Lier D, Geven C, Leijte GP, Pickkers P. Experimental human endotoxemia as a model of systemic inflammation. Biochimie. 2019;159:99–106.
doi: 10.1016/j.biochi.2018.06.014
pubmed: 29936295
Akitomi SSY, Tanaka Y, Endo S. Whole blood gene expression profiling in response to treatment for septic shock: a case report. Ann Clin Med Case Rep. 2021;6(17):1–5.
Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med. 1993;328(20):1457–60.
doi: 10.1056/NEJM199305203282005
pubmed: 8479465
Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediators Inflamm. 2016;2016:6978936.
doi: 10.1155/2016/6978936
pubmed: 27293318
pmcid: 4887650
Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190(3):527–34.
doi: 10.1086/422254
pubmed: 15243928
Ikeda T, Ikeda K, Suda S, Ueno T. Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate Immun. 2014;20(8):881–7.
doi: 10.1177/1753425913516885
pubmed: 24398861
Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11(1):141.
doi: 10.1186/s13613-021-00928-z
pubmed: 34568980
pmcid: 8473472
Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205–12.
doi: 10.1007/s00134-018-5463-7
pubmed: 30470853
pmcid: 6280819
Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44(3):193–7.
doi: 10.1159/000475982
pubmed: 28601867
Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med. 1988;318(12):727–32.
doi: 10.1056/NEJM198803243181202
pubmed: 3347221
Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, Chiche JD, Parks T, Chapman SJ, Davenport EE, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2015;3(1):53–60.
doi: 10.1016/S2213-2600(14)70290-5
pubmed: 25533491
pmcid: 4314768
Scherag A, Schoneweck F, Kesselmeier M, Taudien S, Platzer M, Felder M, Sponholz C, Rautanen A, Hill AVS, Hinds CJ, et al. Genetic factors of the disease course after sepsis: a genome-wide study for 28 day mortality. EBioMedicine. 2016;12:239–46.
doi: 10.1016/j.ebiom.2016.08.043
pubmed: 27639821
pmcid: 5078589
Kernan KF, Ghaloul-Gonzalez L, Shakoory B, Kellum JA, Angus DC, Carcillo JA. Adults with septic shock and extreme hyperferritinemia exhibit pathogenic immune variation. Genes Immun. 2019;20(6):520–6.
doi: 10.1038/s41435-018-0030-3
pubmed: 29977033
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
doi: 10.1001/jama.2016.0287
pubmed: 26903338
pmcid: 4968574
Hurley JC. Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect. Toxins (Basel). 2013;5(12):2589–620.
doi: 10.3390/toxins5122589
pubmed: 24351718
Behre G, Schedel I, Nentwig B, Wormann B, Essink M, Hiddemann W. Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother. 1992;36(10):2139–46.
doi: 10.1128/AAC.36.10.2139
pubmed: 1444293
pmcid: 245468
Wortel CH, von der Mohlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ, Smith CR, Allen IE, ten Cate JW. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis. 1992;166(6):1367–74.
doi: 10.1093/infdis/166.6.1367
pubmed: 1431255
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154–62.
doi: 10.1001/jama.2013.2194
pubmed: 23512062
Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg. 2017;1(2):105–13.
doi: 10.1002/ags3.12015
pubmed: 29863114
pmcid: 5881300
Fujimori K, Tarasawa K, Fushimi K. Effects of polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif. 2021;50(4–5):560–5.
doi: 10.1159/000513213
pubmed: 33582663
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.
doi: 10.1001/jama.2009.856
pubmed: 19531784
Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975–84.
doi: 10.1007/s00134-015-3751-z
pubmed: 25862039
pmcid: 4477725
Payen D, Dupuis C, Deckert V, Pais de Barros JP, Rerole AL, Lukaszewicz AC, Coudroy R, Robert R, Lagrost L. Endotoxin mass concentration in plasma is associated with mortality in a multicentric cohort of peritonitis-induced shock. Front Med (Lausanne). 2021;8:749405.
doi: 10.3389/fmed.2021.749405
pubmed: 34778311
Dargent A, Pais De Barros JP, Ksiazek E, Fournel I, Dusuel A, Rerole AL, Choubley H, Masson D, Lagrost L, Quenot JP. Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): a cohort study. Intensive Care Med. 2019;45(11):1678–80.
doi: 10.1007/s00134-019-05749-0
pubmed: 31451860
Carcillo JA, Kellum JA. Is there a role for plasmapheresis/plasma exchange therapy in septic shock, MODS, and thrombocytopenia-associated multiple organ failure? We still do not know–but perhaps we are closer. Intensive Care Med. 2002;28(10):1373–5.
doi: 10.1007/s00134-002-1428-x
pubmed: 12373459
Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014;15(1):218.
doi: 10.1186/1745-6215-15-218
pubmed: 24916483
pmcid: 4066268
Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, Kashani K, Koyner JL, Pannu N, Meersch M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19(6):401–17.
doi: 10.1038/s41581-023-00683-3
pubmed: 36823168
Ronco C, Chawla L, Husain-Syed F, Kellum JA. Rationale for sequential extracorporeal therapy (SET) in sepsis. Crit Care. 2023;27(1):50.
doi: 10.1186/s13054-023-04310-2
pubmed: 36750878
pmcid: 9904264